Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 September 2022.
Key achievements include:
- Second engineering run of PAT-DX1 successfully passes specification testing providing material for final GLP toxicology studies to support Phase-1 clinical trial in 2H CY2023
- Preclinical studies demonstrate PAT-DX1 improves effectiveness of radiation and survival in animal model of high grade glioma – a highly aggressive primary brain cancer
- Olivia Newton-John Cancer Research Institute awarded $100,000 grant to research use of PAT-DX1 and PAT-DX3 in animal models of triple negative breast cancer
- Cash and short-term investments of $7.2M at 30 September 2022